La Jolla Pharmaceutical Company (LJPC)
| Market Cap | 147.86M |
| Revenue (ttm) | 29.72M |
| Net Income (ttm) | -61.18M |
| Shares Out | 27.37M |
| EPS (ttm) | -2.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $5.40 |
| Previous Close | $5.35 |
| Change ($) | 0.05 |
| Change (%) | 0.93% |
| Day's Open | 5.38 |
| Day's Range | 5.20 - 5.84 |
| Day's Volume | 650,455 |
| 52-Week Range | 3.40 - 8.68 |
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patient...
La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patient...
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies...
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Exe...
-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases- -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from...
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights
La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...
SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...
SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...
SAN DIEGO, April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...
The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.
SAN DIEGO, March 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 5.10% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical.
Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended t...
Shares of La Jolla Pharmaceutical Company fell 30% in premarket trading after it announced president and CEO George Tidmarsh had left the company and that the company plans to "re-evaluate it...
SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended t...
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -0.93% and -18.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead ...
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This year, for the first time in many years, active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended ...
While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended t...
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the...
The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.
La Jolla Pharmaceutical announced positive results from its phase 2 study using LJPC-401 to treat patients with hereditary hemochromatosis.
Successful turnaround stories are like Cinderella bioscience stocks. They do not come around often but the profits from a successful turnaround are phenomenal.
La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.
A mid-stage clinical trial has investors excited about the biotech's future.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for ...
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.
About LJPC
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is ... [Read more...]
| Industry Biotechnology | IPO Date Jun 3, 1994 |
| Stock Exchange NASDAQ | Ticker Symbol LJPC |
Financial Performance
In 2019, LJPC's revenue was $23.05 million, an increase of 129.26% compared to the previous year's $10.06 million. Losses were -$116.51 million, -41.59% less than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for LJPC stock is "Buy." The 12-month stock price forecast is 10.92, which is an increase of 102.22% from the latest price.